Cognitive Dysfunction
Drug research and approvals for cognitive Dysfunction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 847 studies of cognitive Dysfunction are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 847
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 847 recruiting on ClinicalTrials.gov ↗- Tau Pathology in the Brain After Hip or Knee Replacement SurgeryNCT07871487 · Not reported · Uppsala University Hospital · starts Apr 1, 2029
- Synbiotic LA-5 and Agave Inulin for Mild Cognitive ImpairmentNCT07818369 · Not applicable · Anahuac University · starts Dec 31, 2026
- PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)NCT07169630 · Phase 1 · National Institute of Mental Health (NIMH) · starts Nov 19, 2026
- Predicting Pre-dementiaNCT07516119 · Not reported · Prevention Research Consortium Corp. · starts Nov 15, 2026
- Evaluating Biomarkers of Cognitive Dysfunction in Patients With CancerNCT07226466 · Not reported · University of California, San Francisco · starts Nov 2, 2026
- CMN LIFU for Enhanced Amyloid Reduction (CLEART Study)NCT07866768 · Not applicable · University of California, San Francisco · starts Nov 1, 2026
- Lactobacillus Acidophilus and Inulin for Cognitive Impairment in ObesityNCT07810517 · Not applicable · Anahuac University · starts Nov 1, 2026
- Prediction and Prevention of Postoperative Mortality and MorbidityNCT06042413 · Not applicable · University of Pittsburgh · starts Oct 23, 2026
- Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot StudyNCT07313540 · Not applicable · The University of Texas Medical Branch, Galveston · starts Oct 22, 2026
- Choose Myself (Before) Losing MyselfNCT07846566 · Not applicable · The Cleveland Clinic · starts Oct 9, 2026
Drug Pipeline
4 approved, 15 in phase 3, 42 in phase 2, 33 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Flortaucipir, Florbetaben, Florbetapir, Flutemetamol
- Donepezil
- Phase 3 Acetylcholinesterase inhibitor
- Metformin
- Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Atorvastatin
- Phase 3 HMG-CoA reductase inhibitor
- Memantine
- Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
- Bexarotene
- Phase 3 Retinoid X receptor agonist
- Duloxetine
- Phase 3 Serotonin transporter inhibitor
- Quetiapine
- Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
- Raloxifene
- Phase 3 Estrogen receptor beta modulator
- Tamoxifen
- Phase 3 Estrogen receptor alpha modulator
- Sertindole
- Phase 3 Dopamine D2 receptor antagonist
- Cholecalciferol
- Phase 3 Vitamin D receptor agonist
- Galantamine
- Phase 3 Acetylcholinesterase inhibitor
- Rivastigmine
- Phase 3 Cholinesterases; ACHE & BCHE inhibitor
- Solanezumab
- Phase 3 Amyloid-beta A4 protein binding agent
- Fenretinide
- Phase 3
- Acetylcysteine
- Phase 2 Glutathione precursor
- Curcumin
- Phase 2
- Human immunoglobulin g
- Phase 2 Replacement therapy, immunomodulatory effects
- Levetiracetam
- Phase 2 Synaptic vesicle glycoprotein 2A modulator
- Encenicline
- Phase 2 Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist
- Davunetide
- Phase 2 Tubulin stabiliser
- Cannabidiol
- Phase 2 Cannabinoid CB1 receptor negative allosteric modulator
- Peptide t
- Phase 2
- Ibuprofen
- Phase 2 Cyclooxygenase inhibitor
- Lamotrigine
- Phase 2 Sodium channel alpha subunit blocker
- Maraviroc
- Phase 2 C-C chemokine receptor type 5 antagonist
- Norepinephrine
- Phase 2 Adrenergic receptor agonist
- Pioglitazone
- Phase 2 Peroxisome proliferator-activated receptor gamma agonist
- Rosiglitazone
- Phase 2 Peroxisome proliferator-activated receptor gamma agonist
- Atomoxetine
- Phase 2 Norepinephrine transporter inhibitor
Showing the 30 furthest along of 90 in trials.
How Its Trials Ended
3,264 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 449 whose ending is known, 37% met their primary endpoint, 11% missed it and 51% stopped early.
- Completed, result not reported1,25839%
- Ongoing1,05232%
- Status unknown50515%
- Met its primary endpoint1685%
- Stopped: other or unclear1324%
- Stopped: enrollment or feasibility542%
- Missed its primary endpoint512%
- Stopped: funding191%
- Stopped: lack of efficacy171%
- Stopped: sponsor or business decision80%
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 4, 1991 | Pramiracetam SulfateFor the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy. | Cambridge Neuroscience, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 15, 2025 | LeqembiLecanemab | Eisai GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA